IL6 and systemic sclerosis: IL-6 is known to promote endothelial cell dysfunction and regulate leucocyte recruitment to the vascular wall [192]; therefore, it is unsurprising that FDA approved IL-6 blockers for arthritic conditions are of interest for treating off-label inflammatory conditions such as systemic sclerosis.